BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shionogi readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Shionogi's drugs run\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07619118-5401@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07619118)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholeste
 rolaemia\nEstimated primary completion: 28 May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07619118
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619131-5401@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07619131)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Laroprovstat\, Rosuvastatin and Placebo on LDL-C in 
 LLT-naïve Patients.\nEstimated primary completion: 30 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07619131
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07265479-1783@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tapinarof: Phase 3 readout est. (NCT07265479)
DESCRIPTION:Tapinarof\, phase 3\, Atopic Dermatitis.\nStudy: A Study to Inv
 estigate Safety and Efficacy of Tapinarof Cream\, 1% in Participants Ages 
 3 Months to < 24 Months With Atopic Dermatitis\nEstimated primary completi
 on: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tapi
 narof#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07265479
URL:https://assetmemo.bio/drug/tapinarof#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05918861-1099@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Dalcetrapib: Phase 3 readout est. (NCT05918861)
DESCRIPTION:Dalcetrapib\, phase 3\, Atherosclerotic Cardiovascular Disease.
 \nStudy: Effect of Dalcetrapib on CV Risk in a Genetically Defined Populat
 ion With a Recent ACS\nEstimated primary completion: August 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/dalcetrapib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05918861
URL:https://assetmemo.bio/drug/dalcetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930507-5401@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07930507)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Laroprovstat\, Rosuvastatin\, and Placebo on LDL-C i
 n LLT-naïve Patients\nEstimated primary completion: 11 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07930507
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393659-1031@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20320914
DTEND;VALUE=DATE:20320915
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 3 readout est. (NCT07393659)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 3\, HIV.\nStudy: A Continued Access Study for Participants Transit
 ioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Par
 ent Studies for HIV Treatment\nEstimated primary completion: 14 September 
 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/dolutegravir#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073936
 59
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
